PGxO and PGxLOD: a reconciliation of pharmacogenomic knowledge of various provenances, enabling further comparison.

Journal: BMC bioinformatics
PMID:

Abstract

BACKGROUND: Pharmacogenomics (PGx) studies how genomic variations impact variations in drug response phenotypes. Knowledge in pharmacogenomics is typically composed of units that have the form of ternary relationships gene variant - drug - adverse event. Such a relationship states that an adverse event may occur for patients having the specified gene variant and being exposed to the specified drug. State-of-the-art knowledge in PGx is mainly available in reference databases such as PharmGKB and reported in scientific biomedical literature. But, PGx knowledge can also be discovered from clinical data, such as Electronic Health Records (EHRs), and in this case, may either correspond to new knowledge or confirm state-of-the-art knowledge that lacks "clinical counterpart" or validation. For this reason, there is a need for automatic comparison of knowledge units from distinct sources.

Authors

  • Pierre Monnin
    Université de Lorraine, CNRS, Inria, LORIA, Nancy, 54000, France. pierre.monnin@loria.fr.
  • Joël Legrand
    Université de Lorraine, CNRS, Inria, LORIA, Nancy, 54000, France.
  • Graziella Husson
    Université de Lorraine, CNRS, Inria, LORIA, Nancy, 54000, France.
  • Patrice Ringot
    LORIA (CNRS, Inria Nancy-Grand Est, University of Lorraine), Campus Scientifique, Nancy, France.
  • Andon Tchechmedjiev
    Laboratory of Informatics, Robotics and Microelectronics of Montpellier (LIRMM), University of Montpellier & CNRS, Montpellier 34090, France.
  • Clement Jonquet
    Stanford Center for Biomedical Informatics Research, 1265 Welch Road, Stanford University School of Medicine, Stanford, CA, 94305-5479, USA.
  • Amedeo Napoli
    Université de Lorraine, CNRS, Inria, LORIA, Nancy, 54000, France.
  • Adrien Coulet
    LORIA (CNRS, Inria Nancy-Grand Est, University of Lorraine), Campus Scientifique, Nancy, France. adrien.coulet@loria.fr.